Drug-induced hypothyroidism in tuberculosis

References

• World Health Organization. Global tuberculosis report 2022 [Internet]. p. 68. Geneva; 2022 [cited 2023 Aug 1]. Available from: https://www.who.int/publications-detail-redirect/9789240061729
   Google Scholar
• Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J. 2017 Mar 1 [cited 2023 Jul 28];49(3):1600803. Internet: https://erj.ersjournals.com/content/49/3/1600803
   PubMed Web of Science ®Google Scholar
• Wilson JW, Tsukayama DT. Extensively Drug-Resistant Tuberculosis: Principles of Resistance, Diagnosis, and Management. Mayo Clin Proc. 2016 Apr;91(4):482–495. doi: 10.1016/j.mayocp.2016.01.014
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis [internet]. p. 40. Geneva; 2021 [cited 2023 Jul 31]. Available from: https://www.who.int/publications-detail-redirect/9789240018662
   Google Scholar
• Salari N, Kanjoori AH, Hosseinian-Far A, et al. Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis. Infect Dis Poverty. 2023 May 25;12(1):57.
   PubMed Web of Science ®Google Scholar
• Pedersen OS, Holmgaard FB, Mikkelsen MKD, et al. Global treatment outcomes of extensively drug-resistant tuberculosis in adults: a systematic review and meta-analysis. J Infect. 2023 Jun 23 [cited 2023 Aug 1]. Internet: https://www.sciencedirect.com/science/article/pii/S0163445323003377
   PubMed Web of Science ®Google Scholar
• Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study. Medicine (Baltimore). 2017 Jul;96(28):e7482.
   PubMed Web of Science ®Google Scholar
• Prasad R, Singh A, Gupta N. Adverse drug reactions in tuberculosis and management. Indian J Tuberc. 2019 Oct;66(4):520–532. doi: 10.1016/j.ijtb.2019.11.005
   PubMedGoogle Scholar
• Prasad R, Singh A, Gupta N. Adverse drug reactions with first-line and second-line drugs in treatment of tuberculosis. Ann Natl Acad Med Sci. 2021 Jan;57(1):15–35. doi: 10.1055/s-0040-1722535
   Google Scholar
• Chung SJ, Byeon SJ, Choi JH. Analysis of adverse drug reactions to first-line anti-tuberculosis drugs using the Korea adverse event reporting system. J Korean Med Sci. 2022 Apr 18;37(16):e128.
   PubMed Web of Science ®Google Scholar
• Setiawan SI, Ascobat P. Adverse reactions to first-line anti-tuberculosis drugs as a risk factor of pulmonary tuberculosis treatment default in Jakarta, Indonesia. Int J Appl Pharm. 2019 Nov;11(Special Issue 6):80–83. doi: 10.22159/ijap.2019.v11s6.33551
   PubMedGoogle Scholar
• Djochie RDA, Anto BP, Opare-Addo MNA. Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study. J Pharm Policy Pract. 2023 Jun 8;16(1):70.
   PubMed Web of Science ®Google Scholar
• Tola HH, Holakouie-Naieni K, Lejisa T, et al. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis. PLoS One. 2019;14(6):e0218487. doi: 10.1371/journal.pone.0218487
   PubMed Web of Science ®Google Scholar
• World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis [Internet]. p. 403. Geneva: World Health Organization; 2014 [cited 2023 Jul 30]. Available from: https://apps.who.int/iris/handle/10665/130918
   Google Scholar
• Gupta A, Kumar V, Natarajan S, et al. Adverse drug reactions & drug interactions in MDR-TB patients. Indian J Tuberculosis. 2020 Dec;67(4):S69–78. doi: 10.1016/j.ijtb.2020.09.027
   PubMedGoogle Scholar
• Bode H, Ivens B, Bschor T, et al. Association of hypothyroidism and clinical depression: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Dec 1;78(12):1375–1383.
   PubMed Web of Science ®Google Scholar
• Loh HH, Lim LL, Yee A, et al. Association between subclinical hypothyroidism and depression: an updated systematic review and meta-analysis. BMC Psychiatry. 2019 Jan 8;19(1):12.
   PubMedGoogle Scholar
• Duko B, Bedaso A, Ayano G. The prevalence of depression among patients with tuberculosis: a systematic review and meta-analysis. Ann Gen Psychiatry. 2020;19:30. doi: 10.1186/s12991-020-00281-8
   PubMed Web of Science ®Google Scholar
• Panati D, Chittooru CS, Madarapu YR, et al. Effect of depression on treatment adherence among elderly tuberculosis patients: a prospective interventional study. Clin Epidemiol Global Health. 2023 Jul 1;22:101338.
   Web of Science ®Google Scholar
• Ruiz-Grosso P, Cachay R, De La Flor A, et al. Association between tuberculosis and depression on negative outcomes of tuberculosis treatment: a systematic review and meta-analysis. Ehtesham HS, editor. PLoS One. 2020 Jan 10;15(1):e0227472 doi: 10.1371/journal.pone.0227472
   PubMed Web of Science ®Google Scholar
• Rouf A, Masoodi MA, Dar MM, et al. Depression among tuberculosis patients and its association with treatment outcomes in district Srinagar. J Clin Tuberc Other Mycobact Dis. 2021 Nov 15;25:100281.
   PubMedGoogle Scholar
• Bares R, Khalid N, Daniel H, et al. Hypothyroidism during second-line treatment of multidrug-resistant tuberculosis: a prospective study. Int J Tuberc Lung Dis. 2016 Jul;20(7):876–881. doi: 10.5588/ijtld.15.0692
   PubMed Web of Science ®Google Scholar
• Dutta BS, Hassan G, Waseem Q, et al. Ethionamide-induced hypothyroidism. Int J Tuberc Lung Dis. 2012 Jan;16(1):141.
   PubMed Web of Science ®Google Scholar
• Mallela AR, Koya R, Nagari SK, et al. Ethionamide: unusual cause of hypothyroidism. J Clin Diagn Res. 2015 Aug;9(8):OD08–9. doi: 10.7860/JCDR/2015/13531.6331
   PubMedGoogle Scholar
• Satti H, Mafukidze A, Jooste PL, et al. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. Int J Tuberc Lung Dis. 2012 Apr;16(4):468–472. doi: 10.5588/ijtld.11.0615
   PubMed Web of Science ®Google Scholar
• Meressa D, Hurtado RM, Andrews JR, et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia–an observational cohort study. Thorax. 2015 Dec;70(12):1181–1188.
   PubMed Web of Science ®Google Scholar
• Biranu E, Wolde M, Edao Negesso A, et al. Thyroid profile and factors associated with hypothyroidism among multidrug-resistant tuberculosis patients attending Saint Peter’s specialized hospital Addis Ababa, Ethiopia. Infect Drug Resist. 2021;14:2675–2684. doi: 10.2147/IDR.S310404
   PubMed Web of Science ®Google Scholar
• Díaz Covarrubias-López TM, Laniado-Laborín R. Reacciones adversas a los fármacos antituberculosis en pacientes con esquemas mixtos. Neumología y cirugía de tórax. 2016 Jun;75(2):149–154.
   Google Scholar
• Munivenkatappa S, Anil S, Naik B, et al. Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field. J Tuberc Res. 2016 Sep;4(3):105–110. doi: 10.4236/jtr.2016.43013
   PubMedGoogle Scholar
• Awad NT, Deokar K, Nair J, et al. Effect of treatment of drug resistant tuberculosis on thyroid stimulating hormone. Eur Respir J. 2016 Sep 1 [cited 2023 Aug 19];48(suppl 60). Available from: https://erj.ersjournals.com/content/48/suppl_60/PA2689
   Google Scholar
• Hallbauer UM, Schaaf HS. Ethionamide-induced hypothyroidism in children. South Afr J Epidemiol Infect. 2011 Jan 1;26(3):161–163.
   Google Scholar
• Chaker L, Razvi S, Bensenor IM, et al. Hypothyroidism. Nat Rev Dis Primers. 2022 May 19;8(1):1–17.
   PubMedGoogle Scholar
• Leung A, Pearce EN, Braverman LE. Role of iodine in thyroid physiology. Expert Rev Endocrinol Metab. 2010 Jul 1;5(4):593–602.
   PubMedGoogle Scholar
• Nedić O. Iodine: physiological importance and food sources. eFood. 2023;4(1):e63.
   Google Scholar
• Lipp HP. Administration and pharmacokinetics of levothyroxine. In: Kahaly G, editor. 70 years of levothyroxine. 1st ed. Cham, Switzerland: Springer International Publishing; 2021. p. 13–22.
   Google Scholar
• Klein I, Danzi S. Thyroid disease and the heart. Curr Probl Cardiol. 2016 Feb;41(2):65–92. doi: 10.1016/j.cpcardiol.2015.04.002
   PubMed Web of Science ®Google Scholar
• Jansen J, Friesema ECH, Kester MHA, et al. Genotype-phenotype relationship in patients with mutations in thyroid hormone transporter MCT8. Endocrinology. 2008 May;149(5):2184–2190. doi: 10.1210/en.2007-1475
   PubMed Web of Science ®Google Scholar
• Peeters RP, Visser TJ, Metabolism of thyroid hormone. In Endotext [internet]. MDText.com, Inc.; 2017. [cited 2023 Jul 5]. https://www.ncbi.nlm.nih.gov/sites/books/NBK285545/
   Google Scholar
• Teumer A, Chaker L, Groeneweg S, et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nat Commun. 2018 Oct 26;9(1):4455. doi: 10.1038/s41467-018-06356-1
   PubMedGoogle Scholar
• Rizzo LFL, Mana DL, Serra HA. Drug-induced hypothyroidism. Med (B Aires). 2017;77(5):394–404.
   PubMed Web of Science ®Google Scholar
• Burch HB, Ingelfinger JR. Drug effects on the thyroid. N Engl J Medicina. 2019 Aug 21 [cited 2023 Aug 5];381(8): 749–761. doi: 10.1056/NEJMra1901214
   PubMed Web of Science ®Google Scholar
• Abdulrahman RM, Verloop H, Hoftijzer H, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab. 2010 Aug 1;95(8):3758–3762.
   PubMed Web of Science ®Google Scholar
• Kappers MHW, van Esch JHM, Smedts FMM, et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab. 2011 Oct 1;96(10):3087–3094. doi: 10.1210/jc.2011-1172
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Goyal A, Kaur P, et al. Anticancer drug-induced thyroid dysfunction. Eur Endocrinol. 2020 Feb [cited 2023 Aug 14];16(1):32. Available from: https://www.touchendocrinology.com/thyroid/journal-articles/anticancer-drug-induced-thyroid-dysfunction/
   PubMedGoogle Scholar
• Montanelli L, Benvenga S, Hegedüs L, et al. Drugs and other substances interfering with thyroid function. In: Vitti P, and Hegedüs L, editors. Thyroid diseases: pathogenesis, diagnosis, and treatment. Cham, Switzerland: Springer International Publishing; 2018. p. 733–761.
   Google Scholar
• Sharma SK, Dheda K. What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment? Indian J Med Res. 2019 Mar;149(3):309–312. doi: 10.4103/ijmr.IJMR_579_19
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment [Internet]. p. 72. Geneva; 2022 [cited 2023 Aug 5]. Available from: https://www.who.int/publications-detail-redirect/9789240048126
   Google Scholar
• Kim HJ, Lee YJ, Song MJ, et al. Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis. Sci Rep. 2023 Jul 12;13(1):11275. doi: 10.1038/s41598-023-38394-1
   PubMed Web of Science ®Google Scholar
• Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 2013 Mar;3(1):37–49. doi: 10.1016/j.jceh.2012.12.001
   PubMedGoogle Scholar
• Vale N, Gomes P, Santos HA. Metabolism of the antituberculosis drug ethionamide. Curr Drug Metab. 2013 Jan;14(1):151–158. doi: 10.2174/138920013804545151
   PubMed Web of Science ®Google Scholar
• Thee S, Garcia-Prats AJ, Donald PR, et al. A review of the use of ethionamide and prothionamide in childhood tuberculosis. Tuberculosis (Edinb). 2016 Mar;97:126–136. doi: 10.1016/j.tube.2015.09.007
   PubMed Web of Science ®Google Scholar
• da Silva DA, Ferreira NV, Rego AM, et al. Integrated analysis of ethionamide resistance loci in Mycobacterium tuberculosis clinical isolates. Tuberculosis. 2018 Dec 1;113:163–174.
   PubMed Web of Science ®Google Scholar
• Schaaf HS, Thee S, van der Laan L, et al. Adverse effects of oral second-line antituberculosis drugs in children. Expert Opin Drug Saf. 2016 Oct;15(10):1369–1381. doi: 10.1080/14740338.2016.1216544
   PubMed Web of Science ®Google Scholar
• Cheung YMM, Van K, Lan L, et al. Hypothyroidism associated with therapy for multi-drug-resistant tuberculosis in Australia. Intern Med J. 2019;49(3):364–372. doi: 10.1111/imj.14085
   PubMed Web of Science ®Google Scholar
• Lesmana R, Shidqi F, Goenawan H, et al. The potential interaction of ethionamide-thyroid hormone receptor induces hypothyroidism. Pharmacogn J. 2021;13(5):1174–1179. doi: 10.5530/pj.2021.13.150
   Google Scholar
• Donald PR, Diacon AH. Para-aminosalicylic acid: the return of an old friend. Lancet Infect Dis. 2015 Sep;15(9):1091–1099. doi: 10.1016/S1473-3099(15)00263-7
   PubMed Web of Science ®Google Scholar
• Thee S, Zöllner EW, Willemse M, et al. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis. 2011 Sep;15(9):1191–3, i. i. doi: 10.5588/ijtld.10.0707
   PubMed Web of Science ®Google Scholar
• Parvez MM, Shin HJ, Jung JA, et al. Evaluation of para-aminosalicylic acid as a substrate of multiple solute carrier uptake transporters and possible drug interactions with nonsteroidal anti-inflammatory drugs in vitro. Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/aac.02392-16.
   PubMed Web of Science ®Google Scholar
• Chaker L, Bianco AC, Jonklaas J, et al. Hypothyroidism. Lancet. 2017 Sep 23;390(10101):1550–1562.
   PubMed Web of Science ®Google Scholar
• McDermott MT. Hypothyroidism. Ann Intern Med. 2020 Jul 7;173(1):ITC1–16.
   PubMed Web of Science ®Google Scholar
• Filate M, Mehari Z, Alemu YM. Longitudinal body weight and sputum conversion in patients with tuberculosis, Southwest Ethiopia: a retrospective follow-up study. BMJ Open. 2018 Sep 1;8(9):e019076.
   PubMed Web of Science ®Google Scholar
• Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American thyroid Association. Endocr Pract. 2012 Nov 1;18(6):988–1028. doi: 10.4158/EP12280.GL
   PubMed Web of Science ®Google Scholar
• Kosack CS, Page AL, Van Hulsteijn LT, et al. TSH-CHECK-1 test: diagnostic accuracy and potential application to initiating treatment for hypothyroidism in patients on anti-tuberculosis drugs. PLoS One. 2012;7(3):e33704. doi: 10.1371/journal.pone.0033704
   PubMed Web of Science ®Google Scholar
• Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid hormone replacement. Thyroid. 2014 Dec 1;24(12):1670–1751. doi: 10.1089/thy.2014.0028
   PubMed Web of Science ®Google Scholar
• Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005 Jan;90(1):124–127. doi: 10.1210/jc.2004-1306
   PubMed Web of Science ®Google Scholar
• Ratanapornsompong G, Sriphrapradang C. Appropriate dose of levothyroxine replacement therapy for hypothyroid obese patients. J Clin Transl Endocrinol. 2021 Sep;25:100264. doi: 10.1016/j.jcte.2021.100264
   PubMedGoogle Scholar
• Cunningham JJ, Barzel US. Lean body mass is a predictor of the daily requirement for thyroid hormone in older men and women. J Am Geriatr Soc. 1984;32(3):204–207. doi: 10.1111/j.1532-5415.1984.tb02003.x
   PubMed Web of Science ®Google Scholar